NASDAQ:INGN - Inogen Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $143.33 +4.34 (+3.12 %) (As of 02/22/2019 04:00 PM ET)Previous Close$143.33Today's Range$139.1244 - $143.8352-Week Range$110.51 - $287.79Volume429,393 shsAverage Volume548,814 shsMarket Capitalization$3.06 billionP/E Ratio109.41Dividend YieldN/ABeta1.65 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Inogen, Inc., a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. It offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; and Inogen At Home stationary oxygen concentrators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was founded in 2001 and is headquartered in Goleta, California. Receive INGN News and Ratings via Email Sign-up to receive the latest news and ratings for INGN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical appliances & supplies Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:INGN Previous Symbol CUSIPN/A CIK1294133 Webwww.inogen.com Phone805-562-0500Debt Debt-to-Equity RatioN/A Current Ratio6.49 Quick Ratio5.83Price-To-Earnings Trailing P/E Ratio109.41 Forward P/E Ratio67.93 P/E Growth2.64 Sales & Book Value Annual Sales$249.44 million Price / Sales12.27 Cash Flow$1.9982 per share Price / Cash Flow71.73 Book Value$10.88 per share Price / Book13.17Profitability EPS (Most Recent Fiscal Year)$1.31 Net Income$21 million Net Margins12.28% Return on Equity18.91% Return on Assets15.43%Miscellaneous Employees770 Outstanding Shares21,350,000Market Cap$3.06 billion Next Earnings Date2/26/2019 (Confirmed) OptionableOptionable Inogen (NASDAQ:INGN) Frequently Asked Questions What is Inogen's stock symbol? Inogen trades on the NASDAQ under the ticker symbol "INGN." How were Inogen's earnings last quarter? Inogen Inc (NASDAQ:INGN) issued its quarterly earnings results on Tuesday, August, 7th. The medical technology company reported $0.65 EPS for the quarter, topping the Zacks' consensus estimate of $0.44 by $0.21. The medical technology company earned $97.24 million during the quarter, compared to analysts' expectations of $81.61 million. Inogen had a return on equity of 18.91% and a net margin of 12.28%. View Inogen's Earnings History. When is Inogen's next earnings date? Inogen is scheduled to release their next quarterly earnings announcement on Tuesday, February 26th 2019. View Earnings Estimates for Inogen. How can I listen to Inogen's earnings call? Inogen will be holding an earnings conference call on Tuesday, February 26th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8552388123. What price target have analysts set for INGN? 6 Wall Street analysts have issued 1 year target prices for Inogen's stock. Their predictions range from $170.00 to $290.00. On average, they anticipate Inogen's share price to reach $235.60 in the next twelve months. This suggests a possible upside of 64.4% from the stock's current price. View Analyst Price Targets for Inogen. What is the consensus analysts' recommendation for Inogen? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inogen in the last year. There are currently 1 hold rating, 4 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Inogen. What are Wall Street analysts saying about Inogen stock? Here are some recent quotes from research analysts about Inogen stock: 1. According to Zacks Investment Research, "Inogen outperformed the industry in a year’s time. The company continues to gain from its strong portfolio of portable oxygen concentrators (POC) which has been lending it a competitive edge in the MedTech space. Solid business-to-business revenues also buoy optimism. These apart, the company’s direct-to-consumer unit performed exceedingly well in recent times. Moreover, management remains optimistic about its international revenues, which saw solid growth in Europe in recent times. The raised revenue guidance for 2018 is also an added positive. Inogen issued a bullish guidance for 2019 as well. On the flip side, Inogen’s rental revenues declined on a year-over-year basis in recent times. In fact, the company expects rental revenues to remain down in 2018 and grow modestly in 2019. Rising operating expenses are discouraging as well. In the LTOT market, POC adoption continues to face significant headwinds." (2/14/2019) 2. Needham & Company LLC analysts commented, "INGN beat consensus revenue and EPS expectations in 3Q18 and management raised guidance for revenue and net income. The revenue upside was mainly driven by the DTC sales force expansion. Gross margin was up Y/ Y and beat our estimate while operating margin was down Y/Y and just missed our estimate. INGN continues to see the benefit of its DTC sales force expansion as DTC sales grew 66% in 3Q18 and management reiterated its plans to expand its Cleveland sales team to ~330 reps. We expect the ongoing sales force expansion, new product cycle, and the market shift to POCs to sustain strong growth and drive additional upside to consensus and we reiterate our Buy rating." (11/7/2018) Has Inogen been receiving favorable news coverage? Media stories about INGN stock have trended somewhat positive this week, InfoTrie Sentiment reports. The research group rates the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Inogen earned a coverage optimism score of 1.7 on InfoTrie's scale. They also assigned news coverage about the medical technology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near term. Who are some of Inogen's key competitors? Some companies that are related to Inogen include Steris (STE), WILLIAM DEMANT/ADR (WILYY), MSA Safety (MSA), Wright Medical Group (WMGI), Avanos Medical (AVNS), Establishment Labs (ESTA), Invacare (IVC), Sientra (SIEN), RTI Surgical (RTIX), Lakeland Industries (LAKE), ConforMIS (CFMS), Rewalk Robotics (RWLK), COLLPLANT HOLDI/S (CLGN), Precision Therapeutics (AIPT) and NanoVibronix (NAOV). What other stocks do shareholders of Inogen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Inogen investors own include NVIDIA (NVDA), Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Netflix (NFLX), Alibaba Group (BABA), Medivation (MDVN), ABIOMED (ABMD), Adobe (ADBE) and Micron Technology (MU). Who are Inogen's key executives? Inogen's management team includes the folowing people: Mr. Scott Wilkinson, CEO, Pres & Director (Age 54)Mr. Brenton Taylor, Exec. VP of Engineering (Age 38)Ms. Alison Perry Bauerlein, Exec. VP of Fin., CFO, Corp. Sec. & Treasurer (Age 38)Mr. Byron Myers, Exec. VP of Sales & Marketing (Age 40)Mr. Bart Sanford, Exec. VP of Operations Who are Inogen's major shareholders? Inogen's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (10.46%), Dimensional Fund Advisors LP (1.65%), New York State Common Retirement Fund (1.44%), Northern Trust Corp (1.38%), Jennison Associates LLC (1.09%) and Geode Capital Management LLC (0.96%). Company insiders that own Inogen stock include Alison Bauerlein, Brenton Taylor, Byron Myers, Heath Lukatch, Heather D Rider, Loren L Mcfarland, Matt Scribner, Ray Benjamin M Anderson, Raymond Huggenberger and Scott Wilkinson. View Institutional Ownership Trends for Inogen. Which institutional investors are selling Inogen stock? INGN stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Prudential Financial Inc., Acadian Asset Management LLC, Jane Street Group LLC, Virtu Financial LLC, Timpani Capital Management LLC, Public Employees Retirement System of Ohio and New York State Common Retirement Fund. Company insiders that have sold Inogen company stock in the last year include Alison Bauerlein, Brenton Taylor, Byron Myers, Heath Lukatch, Heather D Rider, Loren L Mcfarland, Matt Scribner, Ray Benjamin M Anderson, Raymond Huggenberger and Scott Wilkinson. View Insider Buying and Selling for Inogen. Which institutional investors are buying Inogen stock? INGN stock was acquired by a variety of institutional investors in the last quarter, including Thrivent Financial for Lutherans, Jennison Associates LLC, BlackRock Inc., Polar Capital LLP, Kornitzer Capital Management Inc. KS, Northern Trust Corp, Peregrine Capital Management LLC and American International Group Inc.. View Insider Buying and Selling for Inogen. How do I buy shares of Inogen? Shares of INGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Inogen's stock price today? One share of INGN stock can currently be purchased for approximately $143.33. How big of a company is Inogen? Inogen has a market capitalization of $3.06 billion and generates $249.44 million in revenue each year. The medical technology company earns $21 million in net income (profit) each year or $1.31 on an earnings per share basis. Inogen employs 770 workers across the globe. What is Inogen's official website? The official website for Inogen is http://www.inogen.com. How can I contact Inogen? Inogen's mailing address is 326 BOLLAY DRIVE, GOLETA CA, 93117. The medical technology company can be reached via phone at 805-562-0500 or via email at [email protected] MarketBeat Community Rating for Inogen (NASDAQ INGN)Community Ranking: 3.2 out of 5 ( )Outperform Votes: 294 (Vote Outperform)Underperform Votes: 166 (Vote Underperform)Total Votes: 460MarketBeat's community ratings are surveys of what our community members think about Inogen and other stocks. Vote "Outperform" if you believe INGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INGN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/23/2019 by MarketBeat.com StaffFeatured Article: What is a Special Dividend?